Quick filters
- Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C Business Wire | Friday November 4, 2011 9:00AM
- Vertex Announces Webcasts of Two Investor Presentations Business Wire | Thursday November 3, 2011 5:21PM
- Phase 3 Study of KALYDECO™ (ivacaftor) in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks Business Wire | Thursday November 3, 2011 9:34AM
- Data from the First Part of a Phase 2 Study Support the Approach of Treating the Most Common Form of Cystic Fibrosis (F508del) by Targeting the Underlying Cause of the Disease With a Combination of KALYDECO™ (ivacaftor) and VX-809 Business Wire | Thursday November 3, 2011 9:20AM
- New England Journal of Medicine Publishes Data from Phase 3 STRIVE Study of KALYDECOTM (ivacaftor) in People Ages 12 and Older with a Specific Type of Cystic Fibrosis Business Wire | Wednesday November 2, 2011 5:00PM
- Vertex Reports Profitable Third Quarter and Provides Updates on INCIVEKTM (telaprevir) Launch and Medicines in Development Business Wire | Thursday October 27, 2011 4:00PM
- Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK™ Combination Therapy Business Wire | Monday October 24, 2011 4:33PM
- Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology Business Wire | Monday October 24, 2011 4:00PM
- Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK™ Combination Therapy Business Wire | Monday October 24, 2011 8:34AM
- Vertex Submits Application for Priority Review and Approval of KALYDECO™ (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis Business Wire | Wednesday October 19, 2011 8:00AM
- INCIVEK™ (telaprevir) Now Available in Canada for People with Hepatitis C Business Wire | Tuesday October 11, 2011 8:00AM
- Vertex Announces the Date of its Third Quarter 2011 Financial Results Conference Call and Webcast Business Wire | Thursday October 6, 2011 4:15PM
- Vertex Announces Presentation of New Data on VX-770 and VX-809 at North American Cystic Fibrosis Conference Business Wire | Monday October 3, 2011 9:08AM
- Vertex to Present New Data from Hepatitis C Development Program at AASLD Annual Meeting Business Wire | Friday September 30, 2011 10:45AM
- Vertex Announces Webcast of its Presentations at Two Investor Conferences Business Wire | Friday September 16, 2011 4:15PM
- Vertex Named Top Biopharma Employer by Science Business Wire | Thursday September 15, 2011 2:25PM
- New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C Business Wire | Wednesday September 14, 2011 5:00PM
- Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis Business Wire | Tuesday September 6, 2011 7:30AM
- Vertex Announces Webcast of its Presentations at Two Investor Conferences Business Wire | Thursday September 1, 2011 4:30PM
- Health Canada Approves INCIVEK™ (telaprevir) for People With Hepatitis C Business Wire | Monday August 22, 2011 7:30AM
Live Discussion of VRTX on StockTwits